Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults.

Gallieni M, Hollenbeck M, Inston N, Kumwenda M, Powell S, Tordoir J, Al Shakarchi J, Berger P, Bolignano D, Cassidy D, Chan TY, Dhondt A, Drechsler C, Ecder T, Finocchiaro P, Haller M, Hanko J, Heye S, Ibeas J, Jemcov T, Kershaw S, Khawaja A, Labriola L, Lomonte C, Malovrh M, Marti I Monros A, Matthew S, McGrogan D, Meyer T, Mikros S, Nistor I, Planken N, Roca-Tey R, Ross R, Troxler M, van der Veer S, Vanholder R, Vermassen F, Welander G, Wilmink T, Koobasi M, Fox J, Van Biesen W, Nagler E.

Nephrol Dial Transplant. 2019 Jun 1;34(Supplement_2):ii1-ii42. doi: 10.1093/ndt/gfz072. No abstract available.

PMID:
31192372
2.

Dysmetabolic markers predict outcomes in autosomal dominant polycystic kidney disease.

Kocyigit I, Ozturk F, Eroglu E, Karaca Z, Kaynar AS, Cetin M, Tokgoz B, Sipahioglu MH, Bayramov R, Sen A, Oymak O, Ecder T, Axelsson J.

Clin Exp Nephrol. 2019 May 27. doi: 10.1007/s10157-019-01748-z. [Epub ahead of print]

PMID:
31134465
3.

Which dialysis modality is better for the heart?

Ecder T.

Turk Kardiyol Dern Ars. 2019 Mar;47(2):85-87. doi: 10.5543/tkda.2019.91589. No abstract available.

4.

Fabry Disease Prevalence in Renal Replacement Therapy in Turkey.

Yalın SF, Eren N, Sinangil A, Yilmaz VT, Tatar E, Ucar AR, Sevinc M, Can Ö, Gurkan A, Arik N, Alisir Ecder S, Uyar M, Yasar M, Gulcicek S, Mese M, Dheir H, Cakir U, Köksal Cevher Ş, Turkmen K, Guven B, Guven Taymez D, Erkalma Senates B, Ecder T, Kocak H, Uslu A, Demir E, Basturk T, Ogutmen MB, Kinalp C, Dursun B, Bicik Bahcebasi Z, Sipahi S, Dede F, Oruc M, Caliskan Y, Genc A, Yelken B, Altıparmak MR, Turkmen A, Seyahi N.

Nephron. 2019;142(1):26-33. doi: 10.1159/000496620. Epub 2019 Feb 8.

PMID:
30739116
5.

The Association of Mediterranean and DASH Diets with Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study.

Saglimbene VM, Wong G, Craig JC, Ruospo M, Palmer SC, Campbell K, Garcia-Larsen V, Natale P, Teixeira-Pinto A, Carrero JJ, Stenvinkel P, Gargano L, Murgo AM, Johnson DW, Tonelli M, Gelfman R, Celia E, Ecder T, Bernat AG, Del Castillo D, Timofte D, Török M, Bednarek-Skublewska A, Duława J, Stroumza P, Hoischen S, Hansis M, Fabricius E, Felaco P, Wollheim C, Hegbrant J, Strippoli GFM.

J Am Soc Nephrol. 2018 Jun;29(6):1741-1751. doi: 10.1681/ASN.2018010008. Epub 2018 Apr 25.

6.

Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study.

Saglimbene VM, Wong G, Ruospo M, Palmer SC, Campbell K, Larsen VG, Natale P, Teixeira-Pinto A, Carrero JJ, Stenvinkel P, Gargano L, Murgo AM, Johnson DW, Tonelli M, Gelfman R, Celia E, Ecder T, Bernat AG, Del Castillo D, Timofte D, Török M, Bednarek-Skublewska A, Duława J, Stroumza P, Hoischen S, Hansis M, Fabricius E, Wollheim C, Hegbrant J, Craig JC, Strippoli GFM.

Clin Nutr. 2019 Feb;38(1):429-437. doi: 10.1016/j.clnu.2017.11.020. Epub 2017 Dec 6.

7.

International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.

Rayner HC, Larkina M, Wang M, Graham-Brown M, van der Veer SN, Ecder T, Hasegawa T, Kleophas W, Bieber BA, Tentori F, Robinson BM, Pisoni RL.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2000-2007. doi: 10.2215/CJN.03280317. Epub 2017 Sep 18.

8.

Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function.

Kocyigit I, Taheri S, Sener EF, Eroglu E, Ozturk F, Unal A, Korkmaz K, Zararsiz G, Sipahioglu MH, Ozkul Y, Tokgoz B, Oymak O, Ecder T, Axelsson J.

BMC Nephrol. 2017 May 30;18(1):179. doi: 10.1186/s12882-017-0600-z.

9.

The incidence of new onset diabetes after transplantation and related factors: Single center experience.

Sinangil A, Celik V, Barlas S, Koc Y, Basturk T, Sakaci T, Akin EB, Ecder T.

Nefrologia. 2017 Mar - Apr;37(2):181-188. doi: 10.1016/j.nefro.2016.11.022. Epub 2017 Mar 2. English, Spanish.

10.

Nebivolol can be used for combination therapy in patients with autosomal dominant polycystic kidney disease.

Kocyigit I, Eroglu E, Ecder T.

Expert Opin Pharmacother. 2017 Mar;18(4):455. doi: 10.1080/14656566.2017.1293653. Epub 2017 Feb 17. No abstract available.

PMID:
28234564
11.

Depression and all-cause and cardiovascular mortality in patients on haemodialysis: a multinational cohort study.

Saglimbene V, Palmer S, Scardapane M, Craig JC, Ruospo M, Natale P, Gargano L, Leal M, Bednarek-Skublewska A, Dulawa J, Ecder T, Stroumza P, Marco Murgo A, Schön S, Wollheim C, Hegbrant J, Strippoli GF.

Nephrol Dial Transplant. 2017 Feb 1;32(2):377-384. doi: 10.1093/ndt/gfw016.

PMID:
28186569
12.

Frequency of Nerve Root Sleeve Cysts in Autosomal Dominant Polycystic Kidney Disease.

Aşık M, Tufan F, Akpınar TS, Akalın N, Ceyhan E, Tunç N, Hasıloğlu ZI, Altıparmak MR, Ecder T, Albayram S.

Balkan Med J. 2016 Nov;33(6):652-656. Epub 2016 Nov 1.

13.

Toll-Like Receptors in the Progression of Autosomal Dominant Polycystic Kidney Disease.

Kocyigit I, Sener EF, Taheri S, Eroglu E, Ozturk F, Unal A, Zararsiz G, Uzun I, Imamoglu H, Sipahioglu MH, Tokgoz B, Oymak O, Ecder T.

Ther Apher Dial. 2016 Dec;20(6):615-622. doi: 10.1111/1744-9987.12458. Epub 2016 Dec 7.

PMID:
27928906
14.

The Dialysis Outcomes and Practice Patterns Study (DOPPS) in Turkey.

Ecder T, Utas C, Ates K, Bieber B, Robinson BM, Pisoni RL, Süleymanlar G.

Hemodial Int. 2017 Jul;21(3):430-439. doi: 10.1111/hdi.12504. Epub 2016 Oct 25.

PMID:
27781388
15.

Prevalence of Chronic Kidney Disease in Turkish Adults With Obesity and Metabolic Syndrome: A Post Hoc Analysis from Chronic Renal Disease in Turkey Study.

Arinsoy T, Deger SM, Ates K, Altun B, Ecder T, Camsari T, Serdengecti K, Suleymanlar G.

J Ren Nutr. 2016 Nov;26(6):373-379. doi: 10.1053/j.jrn.2016.08.004. Epub 2016 Sep 15.

PMID:
27641823
16.

Synthetic Cannabinoid Induced acute Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Report and Review of Literature.

Sinangil A, Celik V, Kockar A, Ecder T.

J Clin Diagn Res. 2016 May;10(5):OD31-2. doi: 10.7860/JCDR/2016/18762.7826. Epub 2016 May 1.

17.

New-Onset Diabetes After Kidney Transplantation and Pretransplant Hypomagnesemia.

Sinangil A, Celik V, Barlas S, Sakaci T, Koc Y, Basturk T, Akin EB, Ecder T.

Prog Transplant. 2016 Mar;26(1):55-61. doi: 10.1177/1526924816633949.

PMID:
27136250
18.

Is glomerular filtration rate a marker of severity of coronary heart disease?

Ecder T.

Turk Kardiyol Dern Ars. 2016 Mar;44(2):98-9. doi: 10.5543/tkda.2016.34901. No abstract available.

19.

Statins in the treatment of autosomal dominant polycystic kidney disease.

Ecder T.

Nephrol Dial Transplant. 2016 Aug;31(8):1194-6. doi: 10.1093/ndt/gfv449. Epub 2016 Jan 26. No abstract available.

PMID:
26908774
20.

Renal function and diffusion-weighted imaging: a new method to diagnose kidney failure before losing half function.

Emre T, Kiliçkesmez Ö, Büker A, İnal BB, Doğan H, Ecder T.

Radiol Med. 2016 Mar;121(3):163-72. doi: 10.1007/s11547-015-0579-0. Epub 2015 Sep 21.

PMID:
26392392
21.

Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report.

Api O, Breyman C, Çetiner M, Demir C, Ecder T.

Turk J Obstet Gynecol. 2015 Sep;12(3):173-181. doi: 10.4274/tjod.01700. Epub 2015 Sep 15. Review.

22.

Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study.

Palmer SC, Ruospo M, Campbell KL, Garcia Larsen V, Saglimbene V, Natale P, Gargano L, Craig JC, Johnson DW, Tonelli M, Knight J, Bednarek-Skublewska A, Celia E, Del Castillo D, Dulawa J, Ecder T, Fabricius E, Frazão JM, Gelfman R, Hoischen SH, Schön S, Stroumza P, Timofte D, Török M, Hegbrant J, Wollheim C, Frantzen L, Strippoli GF; DIET-HD Study investigators.

BMJ Open. 2015 Mar 20;5(3):e006897. doi: 10.1136/bmjopen-2014-006897.

23.

Renal and metabolic effects of valsartan.

Ecder T.

Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S14-9. doi: 10.5152/akd.2014.00003. Review.

24.

Should transplant ureter be stented routinely or not?

Sinangil A, Celik V, Barlas S, Akin EB, Ecder T.

Eur Rev Med Pharmacol Sci. 2014;18(23):3551-6.

25.

Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients.

Yelken B, Gorgulu N, Gursu M, Yazici H, Caliskan Y, Telci A, Ozturk S, Kazancioglu R, Ecder T, Bozfakioglu S.

Adv Perit Dial. 2014;30:5-10.

PMID:
25338414
26.

Building a network of ADPKD reference centres across Europe: the EuroCYST initiative.

Petzold K, Gansevoort RT, Ong AC, Devuyst O, Rotar L, Eckardt KU, Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra R, Budde K, Le Meur Y, Wüthrich RP, Serra AL.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv26-32. doi: 10.1093/ndt/gfu091. Erratum in: Nephrol Dial Transplant. 2014 Dec;29(12):2353.

27.
28.

Author's reply.

Turkmen K, Tufan F, Engin S, Akpinar T, Oflaz H, Ecder T.

Indian J Nephrol. 2014 Jan;24(1):66. No abstract available.

29.

Do ketoanalogues still have a role in delaying dialysis initiation in CKD predialysis patients?

Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecder T, Fouque D, Garneata L, Lin S, Mitch W, Teplan V, Yu X, Zakar G.

Semin Dial. 2013 Nov-Dec;26(6):714-9. doi: 10.1111/sdi.12132. Epub 2013 Sep 9. Review.

PMID:
24016150
30.

Cardiovascular complications in autosomal dominant polycystic kidney disease.

Ecder T.

Curr Hypertens Rev. 2013 Feb;9(1):2-11. Review.

PMID:
23971638
31.

Cystatin C is better than albuminuria as a predictor of pulse wave velocity in hypertensive patients.

Ozkok A, Akpinar TS, Tufan F, Kaya O, Bozbey HU, Atas R, Toz B, Atay K, Yilmaz E, Besiroglu M, Nas K, Hadrovic N, Illyés M, Ecder T.

Clin Exp Hypertens. 2014;36(4):222-6. doi: 10.3109/10641963.2013.804548. Epub 2013 Jul 12.

PMID:
23848132
32.

Neutrophil-to-lymphocyte ratio, insulin resistance, and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.

Turkmen K, Tufan F, Selçuk E, Akpınar T, Oflaz H, Ecder T.

Indian J Nephrol. 2013 Jan;23(1):34-40. doi: 10.4103/0971-4065.107195.

33.

Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.

Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, Caliskan Y, Alisir S, Yazici H, Ecder T.

Clin Exp Nephrol. 2013 Jun;17(3):345-51. doi: 10.1007/s10157-012-0706-3. Epub 2012 Oct 20.

PMID:
23085781
34.

Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: results from the CREDIT study.

Altun B, Süleymanlar G, Utaş C, Arınsoy T, Ateş K, Ecder T, Camsarı T, Serdengeçti K.

Kidney Blood Press Res. 2012;36(1):36-46. doi: 10.1159/000339025. Epub 2012 Jul 23.

35.

Cardiac biomarkers and noninvasive predictors of atherosclerosis in chronic peritoneal dialysis patients.

Caliskan Y, Ozkok A, Akagun T, Alpay N, Guz G, Polat N, Tufan F, Ecder T, Bozfakioglu S.

Kidney Blood Press Res. 2012;35(5):340-8. doi: 10.1159/000332084. Epub 2012 Apr 3.

36.

Keto acid therapy in predialysis chronic kidney disease patients: final consensus.

Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecder T, Fouque D, Garneata L, Lin S, Mitch WE, Teplan V, Zakar G, Yu X.

J Ren Nutr. 2012 Mar;22(2 Suppl):S22-4. doi: 10.1053/j.jrn.2011.09.006. No abstract available.

PMID:
22365372
37.

Protein-restricted diets plus keto/amino acids--a valid therapeutic approach for chronic kidney disease patients.

Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecder T, Fouque D, Garneata L, Lin S, Mitch WE, Teplan V, Zakar G, Yu X.

J Ren Nutr. 2012 Mar;22(2 Suppl):S1-21. doi: 10.1053/j.jrn.2011.09.005. Review.

PMID:
22365371
38.

Ambulatory blood pressure monitoring: from old concepts to novel insights.

Kanbay M, Turkmen K, Ecder T, Covic A.

Int Urol Nephrol. 2012 Feb;44(1):173-82. doi: 10.1007/s11255-011-0027-6. Epub 2011 Jul 6. Review.

PMID:
21732053
39.

Insulin resistance and coronary flow velocity reserve in patients with autosomal dominant polycystic kidney disease.

Turkmen K, Tufan F, Alpay N, Kasıkcioglu E, Oflaz H, Ecder SA, Ecder T.

Intern Med J. 2012 Feb;42(2):146-53. doi: 10.1111/j.1445-5994.2010.02404.x.

PMID:
21118411
40.

A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study.

Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, Altiparmak MR, Ecder T, Yilmaz ME, Çamsari T, Başçi A, Odabas AR, Serdengeçti K.

Nephrol Dial Transplant. 2011 Jun;26(6):1862-71. doi: 10.1093/ndt/gfq656. Epub 2010 Nov 4.

41.

Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience.

Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, Cavdar C, Ecder SA, Tokgoz B, Duman N, Duzova A, Cetinkaya R; Turkish Society of Nephrology Polycystic Kidney Disease Working Group.

Nephron Clin Pract. 2011;117(3):c270-5. doi: 10.1159/000320745. Epub 2010 Sep 17.

PMID:
20847569
42.

Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease.

Alisir S, Turkmen K, Alpay N, Elitok A, Oflaz H, Uslu B, Cimen A, Kasikcioglu E, Tufan F, Ecder T.

South Med J. 2010 May;103(5):409-13. doi: 10.1097/SMJ.0b013e3181d80cae.

PMID:
20375940
43.

[Renin inhibition and the kidney].

Ecder T.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:28-31. Turkish.

44.

Assessment of adrenal functions in patients with autosomal dominant polycystic kidney disease.

Tufan F, Uslu B, Cekrezi B, Uysal M, Alpay N, Turkmen K, Disci R, Ozbey NC, Ecder T.

Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):741-6. doi: 10.1055/s-0029-1237698. Epub 2010 Feb 9.

PMID:
20146167
45.

Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.

Locatelli F, Palmer BF, Kashihara N, Ecder T.

Curr Med Res Opin. 2009 Dec;25(12):2933-49. doi: 10.1185/03007990903328231. Review.

PMID:
19835466
46.

Keto-acid therapy in predialysis chronic kidney disease patients: consensus statements.

Aparicio M, Cano NJ, Cupisti A, Ecder T, Fouque D, Garneata L, Liou HH, Lin S, Schober-Halstenberg HJ, Teplan V, Zakar G.

J Ren Nutr. 2009 Sep;19(5 Suppl):S33-5. doi: 10.1053/j.jrn.2009.06.013. No abstract available.

PMID:
19712876
47.

Influence of protein-restricted diets on proteinuria and endothelial dysfunction.

Ecder T.

J Ren Nutr. 2009 Sep;19(5 Suppl):S13-4. doi: 10.1053/j.jrn.2009.06.011. Review. No abstract available.

PMID:
19712868
48.

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Ecder T, Schrier RW.

Nat Rev Nephrol. 2009 Apr;5(4):221-8. doi: 10.1038/nrneph.2009.13. Review.

49.

Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.

Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, Atamer Y.

J Nephrol. 2008 Nov-Dec;21(6):924-30.

PMID:
19034878
50.

The use of bilirubin for the prevention of contrast-induced nephropathy.

Halacli B, Ecder T.

Med Hypotheses. 2009 Feb;72(2):232-3. doi: 10.1016/j.mehy.2008.09.016. Epub 2008 Oct 21. No abstract available.

PMID:
18945551

Supplemental Content

Support Center